"Mergers : Summary of the most important recent developments"* On 17th July, after four months of extensive investigations, the Commission approved the proposed merger between Ciba-Geigy and Sandoz into Novartis. The decision was granted under the condition that the parties comply with an undertaking given in the area of animal health. The activities of Ciba-Geigy and Sandoz overlap in four areas : health care (where Novartis will become the second largest producer behind Glaxo Wellcome), animal health (number 2 behind Pfizer), crop protection (number 1) and seeds (number 2 behind Pioneer). Ciba has an aggregate worldwide turnover of ECU 13.1 billion, Sandoz of ECU 9.1 billion. The Commission decided to open proceedings on
Share on
|
|
The EU Commission approves, subject to remedies, a merger in the health care, animal feed, crop protection and seeds sectors (Ciba-Geigy / Sandoz)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
